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Background and Purpose—In randomized stroke trials, central adjudication of a trial’s primary outcome is regularly 
implemented. However, recent evidence questions the importance of central adjudication in randomized trials. The aim 
of this review was to compare outcomes assessed by central adjudicators with outcomes assessed by site investigators.
Methods—We included randomized stroke trials where the primary outcome had undergone an assessment by site 
investigators and central adjudicators. We searched MEDLINE, EMBASE, CENTRAL (Cochrane Central Register of 
Controlled Trials), Web of Science, PsycINFO, and Google Scholar for eligible studies. We extracted information about 
the adjudication process as well as the treatment effect for the primary outcome, assessed both by central adjudicators 
and by site investigators. We calculated the ratio of these treatment effects so that a ratio of these treatment effects >1 
indicated that central adjudication resulted in a more beneficial treatment effect than assessment by the site investigator. 
A random-effects meta-analysis model was fitted to estimate a pooled effect.
Results—Fifteen trials, comprising 69 560 participants, were included. The primary outcomes included were stroke (8/15, 
53%), a composite event including stroke (6/15, 40%) and functional outcome after stroke measured on the modified 
Rankin Scale (1/15, 7%). The majority of site investigators were blind to treatment allocation (9/15, 60%). On average, 
there was no difference in treatment effect estimates based on data from central adjudicators and site investigators (pooled 
ratio of these treatment effects=1.02; 95% CI, [0.95–1.09]).
Conclusions—We found no evidence that central adjudication of the primary outcome in stroke trials had any impact 
on trial conclusions. This suggests that potential advantages of central adjudication may not outweigh cost and time 
disadvantages in stroke studies if the primary purpose of adjudication is to ensure validity of trial findings.   (Stroke. 
2019;50:2187-2196. DOI: 10.1161/STROKEAHA.119.025019.)
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Central adjudication in randomized trials refers to the eval-uation of outcome data by independent experts who are 
typically part of an event or outcome adjudication commit-
tee.1,2 Events and outcomes can alternatively be assessed by 
local site investigators, and central adjudication is frequently 
seen as a marker of clinical trial quality as it is believed to en-
sure validity of trial results,3 such that regulatory authorities 
have specified the importance of adjudication in guidelines.4,5 
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The adjudication process is thought to improve the precision 
of treatment estimates by reducing random or systematic 
errors.6,7 Furthermore, in open-label studies, adjudication has 
the potential to limit detection bias as adjudicators are una-
ware of treatment allocation.8
Adjudication is regularly implemented in cardiovascular tri-
als,9 but there is inconsistent evidence as to the effect of adjudi-
cation on trial end points in this clinical setting.1,2,7,10–15 Central 
adjudication is potentially a costly and timely process,6,10 and, 
given that many trials are publicly funded, it is important to 
assess adjudication to ensure that trials have an efficient design, 
conduct, and analysis,16 as well as sufficient but not excessive 
regulation and management.17 A Cochrane review18 found no 
evidence that adjudication of subjective events in randomized 
trials had any impact on treatment estimates, but suggested that 
adjudication might have the most effect on outcomes when site 
investigators are not blinded to treatment allocation.
In stroke medicine, secondary analysis of trial data sug-
gests that adjudication makes no meaningful difference to the 
end points of stroke10 or functional outcome.19 Adjudication of 
serious adverse events and stroke type in an acute stroke trial 
showed that adjudication did not alter trial conclusions20,21; in 
contrast, a simulation study suggested that adjudicating the 
modified Rankin Scale in acute stroke trials could lead to 
sample size reductions of up to 20%.22
The aim of this review was to investigate the effects on the 
primary results of stroke trials when using outcomes assessed 
by central adjudicators compared with outcomes assessed by 
site investigators. In addition, we aimed to describe which 
type(s) of stroke trials have adjudicated outcomes, what 
outcomes are adjudicated, and how adjudication has been 
conducted.
Methods
This systematic review and meta-analysis were performed follow-
ing the Preferred Reporting Items for Systematic Review and Meta-
Analyses statement. The review protocol can be found at https://www.
crd.york.ac.uk/prospero/display_record.php?RecordID=56731. 
Supporting, but not individual patient, data are available from the cor-
responding author on reasonable request on receipt of a data sharing 
and use agreement.
Eligibility Criteria
Studies were eligible for inclusion if they (1) described a random-
ized trial; (2) described a stroke trial, where the participants were 
either being treated for stroke or being given an intervention to 
prevent stroke; and (3) the primary outcome had undergone assess-
ment by both site investigators and central adjudicators, with the 
trial providing data to calculate a treatment effect for the primary 
outcome assessed by both central adjudicators and site investiga-
tors separately. Site investigator is a global term describing the per-
sons involved in the trial who assess outcome(s) at each research 
Figure 1. Flow diagram. RCT indicates randomized controlled trials.
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site where study participants are recruited and treated. Adjudicator 
refers to one or more assessors, independent from site investiga-
tors, who use information collected in the trial to assess the same 
outcome.
Outcomes Collected
The primary outcome of each trial was included in this review. If the 
stroke trial had >2 trial arms, then all comparisons were included, but 
for factorial trials, only one comparison was selected. We accounted 
for the correlation between comparisons that used the same control 
group by calculating an adjusted weight for the trial based on this 
additional correlation. Continuous, binary, and categorical (ordinal 
and nominal) outcomes were eligible, as were subjective and objec-
tive outcomes.
Search Strategy
We searched MEDLINE, EMBASE, CENTRAL (Cochrane Central 
Register of Controlled Trials), Web of Science, PsycINFO, and 
Google Scholar for relevant articles (searches from database in-
ception until November 6, 2018; see in the online-only Data 
Supplement). Only the first 300 articles from Google Scholar were 
screened, which is the amount recommended by Haddaway et al23 
to find sufficient gray literature. There were no restrictions on the 
year of publication. Articles not written in English were recorded 
but excluded.
Selection of Studies
Duplicate references were identified, recorded, and then discarded. 
One review author (P.J. Godolphin) screened all titles and abstracts 
in the initial screening. A second review author (Prof Montgomery) 
screened the title and abstract of a random sample of 100 records 
to check this process. If it was unclear from the title and abstract 
whether the record was eligible, then the full text was sought. If the 
article clearly described a secondary analysis of a trial, then the full-
text records were only obtained if the record mentioned adjudication 
as well as satisfying eligibility criteria 1 and 2.
Full-text reports were acquired for all records where potential 
eligibility was unclear. Thus, studies could have multiple records 
(eg, main results and protocol paper). In the full-text screening, 
studies had to satisfy all eligibility criteria to be included in the re-
view. Studies were assessed for inclusion by one review author (P.J. 
Godolphin), with another review author (Prof Montgomery) checking 
the process by assessing a total of 50 random full texts.
  Composite including 
stroke
6 (40%) 39 (53%)  
  Functional outcome 
after stroke
1 (7%) 6 (8%)  
  Other 0 (-) 9 (12%)  
Blinding status of site investigators 0.48‡
  Blind to treatment 
allocation
9 (60%) 37 (50%)  
  Not blind to 
treatment allocation
6 (40%) 37 (50%)  
Data are n (%) unless otherwise stated.
*P value from Fisher exact test.
†P value from Mann-Whitney U test.
‡P value from χ2 test.
Table 1. Continued
Included (n=15)
Potentially 
Eligible but Data 
Not Received 
(n=74) P Value
Table 1. Characteristics of Included Trials and Potentially Eligible Trials
Included (n=15)
Potentially 
Eligible but Data 
Not Received 
(n=74) P Value
Year of main trial publication 0.13*
  1990–2000 2 (13%) 5 (7%)  
  2001–2005 1 (7%) 9 (12%)  
  2006–2010 2 (13%) 20 (27%)  
  2011–2015 6 (40%) 35 (47%)  
  2016–2018 4 (27%) 5 (7%)  
Study design 0.27*
  Parallel 13 (87%) 70 (95%)  
  Factorial 2 (13%) 4 (5%)  
Type of trial 0.16*
  Primary prevention 3 (20%) 34 (46%)  
  Secondary 
prevention
9 (60%) 30 (41%)  
  Acute stroke 3 (20%) 10 (14%)  
No. of randomized groups 0.86*
  2 12 (80%) 61 (82%)  
  3 1 (7%) 7 (9%)  
  ≥4 2 (13%) 6 (8%)  
Participants randomized 0.33†
  Mean (SD) 4637 (5764) 3717 (5246)  
  Median [25th, 75th 
percentile]
2885 [449, 6105] 1633 [439, 4576]  
  Min, Max 129, 21 105 48, 20 702  
No. of sites   0.59†
  Mean (SD) 216 (365) 185 (269)  
  Median [25th, 75th 
percentile]
82 [50, 172] 85 [27, 179]  
  Min, Max 4, 1393 1, 1178  
  Not reported 0 (-) 5 (7%)  
Intervention 0.39*
  Drug 9 (60%) 52 (70%)  
  Surgery/procedure 4 (27%) 18 (24%)  
  Other 2 (13%) 4 (5%)  
Comparator 0.069*
  Placebo 2 (13%) 14 (19%)  
  Standard care 10 (67%) 41 (55%)  
  Active treatment 0 (-) 14 (19%)  
  Surgery/procedure 2 (13%) 5 (7%)  
  Other 1 (7%) 0 (...)  
Primary outcome 0.18*
  Stroke 8 (53%) 20 (27%)  
(Continued )
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Data Extraction
Data from eligible studies were extracted independently by 2 
authors (P.J. Godolphin and E. Patsko) using a piloted data extrac-
tion form. Disagreements were resolved by discussion between 
both review authors. If agreement could not be reached then one 
further review author (Prof Montgomery) assessed the study, with 
the majority decision taken. We recorded whether the central adju-
dicators and site investigators were blind to treatment allocation, 
the number and profession of adjudicators, the information that 
was provided to the adjudicators, the process for adjudication in-
cluding decision making and how disagreements between adjudi-
cators were dealt with.
It was anticipated that outcomes assessed by site investigators 
would not be reported in trial publications. Therefore, if essential 
information was not reported, we emailed the contact author and 
requested unreported data.24
Assessment of Risk of Bias
For each included study, we used the Cochrane risk of bias tool25 to 
assess study quality. Additionally, we assessed the risk of bias asso-
ciated with the process of selecting cases for adjudication, and we 
have termed this adjudication risk of bias. If central adjudicators only 
assess cases identified by site investigators then some bias may re-
main, particularly if site investigators are not blind to treatment allo-
cation and potentially have a biased view of the relative effectiveness 
of the treatments being compared. We created 4 categories for adjudi-
cation risk of bias: (1) Only cases identified by site investigators not 
blind to treatment allocation were selected for adjudication (high risk 
of bias); (2) Only cases identified by site investigators blind to treat-
ment allocation were selected for adjudication (medium risk of bias); 
(3) Either all participants or all suspected cases (eg, using computer 
algorithm to identify possible cases) were selected for adjudication 
(low risk of bias); and (4) It is not clear how cases were selected for 
adjudication (unclear risk of bias).
Statistical Analysis
Continuous variables were summarized with mean and SD or median 
and interquartile range. Categorical variables were described with 
frequency counts and percentages. Mann-Whitney U tests, χ2 tests, 
and Fisher exact tests were used to assess comparability between in-
cluded and potentially eligible but excluded studies.
To compare outcome assessment by central adjudicators and site 
investigators, we calculated the ratio of treatment effects (RTE) for 
each trial. The RTE was determined as the treatment effect estimate 
using outcomes assessed by site investigators to the treatment effect 
estimate using outcomes assessed by central adjudicators. An RTE 
>1 indicated that central adjudication resulted in a more beneficial 
treatment effect. Data were pooled, if appropriate, in a meta-analysis 
using a DerSimonian and Laird random-effects model.
To establish whether central adjudication led to a change in the 
number of events reported, irrespective of the RTE, we compared 
the number of events reported by site investigators to the number re-
ported after central adjudication for each trial. An odds ratio >1 indi-
cates that central adjudication led to more events reported. For trials 
that used the ordinal modified Rankin Scale, we dichotomized so that 
a score of 3 and above indicated an event. As before, data were pooled 
in a meta-analysis using a random-effects model.
The I2 statistic was used to quantify the level of heterogeneity 
between studies. Subgroup analyses and meta-regression were used 
to investigate heterogeneity. We tested the interaction between the 
RTE and the following terms: (1) Adjudication risk of bias (high risk/
medium risk/low risk/unclear risk); (2) Blinding status of site inves-
tigators (blind to allocation/not blind to allocation); (3) Type of inter-
vention (drug/surgery/other); (4) Sample size of trial (continuous); 
and (5) Number of sites (continuous). A sensitivity analysis for the 
meta-analysis of RTEs was performed using a fixed-effect model. All 
analyses were performed in Stata version 15.1 or later.
Results
Search Results
Database searches identified 6339 records and yielded 15 tri-
als of 69 560 participants that were eligible for inclusion26–40 
Table 2. Characteristics of Central Adjudication in Included Trials
Total (n=15)
Adjudicators blind to treatment allocation
  Yes 15 (100%)
Adjudicators blind to assessment of the site investigators
  Yes 6 (40%)
  No 4 (27%)
  Not reported 5 (33%)
Number of adjudicators
  2–4 9 (60%)
  5–9 2 (13%)
  ≥10 4 (27%)
Adjudicators profession*
  Neurologist 14 (93%)
  Cardiologist 3 (20%)
  Other health professional 5 (33%)
  Not a health professional 2 (13%)
  Not reported 1 (7%)
Information provided to adjudicators*
  Medical notes 10 (67%)
  Original case report forms 11 (73%)
  Cranial scans 7 (47%)
  Audio recording 1 (7%)
  Video footage 1 (7%)
  Not reported 3 (20%)
Number of adjudicators per case
  1 5 (33%)
  >1 9 (60%)
  Not reported 1 (7%)
Method used to deal with disagreements
  Each event assessed by single adjudicator, so no 
disagreements
4 (27%)
  Further adjudication 5 (33%)
  Consensus decision between adjudicators/committee 4 (27%)
  Not reported 2 (13%)
How cases were selected for adjudication
  Only those identified by unblinded site investigators 5 (33%)
  Only those identified by blinded site investigators 5 (33%)
  All participants, or all suspected cases identified by 
blinded site investigators
5 (33%)
Data are n (%).
*Categories are not mutually exclusive.
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(Figure 1; Table I in the online-only Data Supplement). An 
additional 74 trials were potentially eligible but did not report 
outcomes assessed by site investigators.
Characteristics of the Potentially Eligible Trials
Table 1 shows the characteristics of all 15 included trials and 
the 74 potentially eligible studies that were excluded because 
of insufficient outcome data. The majority of included trials 
published their main results after 2010, were parallel group, 
secondary prevention, multicenter, and compared 2 random-
ized groups. A common primary outcome for the included 
trials was stroke or a composite event that included stroke 
(14 trials, 93%); site investigators were more likely to have 
assessed the primary outcome blind to treatment allocation. 
Studies that were potentially eligible but not included because 
of insufficient essential information were similar, but tended 
to be from older publications, were more likely to be primary 
prevention trials, had recruited fewer participants, used fewer 
trial sites, and were less likely to have occurrence of stroke as 
the primary outcome.
Characteristics of Central 
Adjudication in Included Trials
For all included trials, central adjudicators were blinded to 
treatment allocation (Table 2). Blinding of central adjudica-
tors to outcome assessment made by site investigators was ei-
ther not done or not reported in 9 of the 15 trials. The number 
of adjudicators involved in each trial ranged from 2 to 28, and 
in over half the studies multiple adjudicators assessed each 
event. Disagreements between adjudicators were dealt with in 
a variety of ways, with use of an additional blinded adjudica-
tion the most common.
Figure 2. Analysis of 18 comparisons from 15 
included trials, comparing the effect size for the 
primary outcome based on whether the assess-
ment was by central adjudicators or not.
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Risk of Bias
Adjudicators commonly assessed only cases reported by 
site investigators, but for all 10 trials where this occurred 
half the site investigators were not blind to treatment allo-
cation. In total, 5 trials were assessed as low adjudication 
risk of bias. All studies were high quality according to the 
Cochrane risk of bias tool (Table II in the online-only Data 
Supplement).
Impact of Central Adjudication on 
Primary Treatment Effect Size
The results of the primary analysis for all included trials using 
both outcome assessment by site investigators and central 
adjudicators are displayed in Figure 2. The meta-analysis of 
RTEs showed no evidence that adjudication altered estimates 
of treatment effect size when compared with assessment by 
site investigators (pooled RTE, 1.02; 95% CI, [0.95–1.09]; 
Figure 3). We found no evidence of any interaction between 
the impact of adjudication on treatment effect estimates and 
blinding of site investigators to the trial allocation, number 
of participants randomized, number of trial sites, type of 
intervention or adjudication risk of bias (Figures I through V 
in the online-only Data Supplement). The sensitivity analysis 
was consistent with the random-effects pooled meta-analysis 
result (Figure VI in the online-only Data Supplement).
Impact of Central Adjudication on 
the Number of Events Reported
We found evidence that central adjudication reduced the 
number of reported events (pooled odds ratio, 0.91; 95% CI, 
[0.88–0.95]; Figure 4) when compared with the number of 
events reported by site investigators.
Discussion
In this meta-analysis of 15 stroke trials, including nearly 
70 000 patients, we found no evidence that central adjudica-
tion of the primary outcome had any substantive impact on 
the primary trial result. Exploration of several prespecified 
subgroups, including trial size, intervention type, and blinding 
status of site investigators supported this finding. However, 
we found evidence that adjudicating resulted in fewer events 
reported for the primary outcome.
Figure 3. Meta-analysis of ratio of treatment effects (RTE) in included studies, using a random-effects model.
D
ow
nloaded from
 http://ahajournals.org by on October 10, 2019
Godolphin et al  Central Adjudication in Stroke Trials  2193
Our findings are consistent with 2 previous reviews. One 
included 10 cardiovascular trials7 and similarly found no 
effect of adjudication versus site reported events (ratio of odds 
ratios, 1.00; 95% CI, [0.97–1.02]). Another was a Cochrane 
Review18 of subjective binary outcomes, across all clinical 
areas, that found adjudication in 47 trials to have no impact 
on treatment effect estimates (ratio of odds ratio, 1.00; 95% 
CI, [0.97–1.04]). The Cochrane Review did suggest, however, 
that adjudication might be important when site investigators 
are not blinded to treatment allocation. This could be because 
of knowledge of the allocation influencing decisions about 
the primary outcome,41,42 but we found no evidence of this in 
our review. This could be because of the outcomes in the tri-
als included in our review (and thus commonly adjudicated 
in stroke trials) are predominantly objective. Therefore, if 
the primary focus of adjudication is to ensure validity of trial 
results, this process may be redundant for trials with objective 
outcomes.
In addition, we found that site investigators over-
reported the number of events for the primary outcome, 
which is consistent with a review of 10 cardiovascular tri-
als7 that showed that adjudication reduced the number of 
reported events. However, this reduction of events had no 
effect on the primary analysis in both ours and the previous 
review, indicating that site investigators over-report events 
in a similar proportion in both treatment arms. Although 
this nondifferential misclassification by site investigators 
will not affect the primary trial analysis, it could affect 
the comparison of the rate of the primary outcome rela-
tive to other events (eg, bleeding with a new anticoagu-
lant). This would influence the risk-benefit calculation of 
bleeding versus prevention of the primary event, which is 
important for both clinicians and regulators. However, it is 
important to note that the process of adjudication in many 
trials does not enable central adjudication to add events as 
adjudicators only assess events reported by site investiga-
tors. Thus, the extent that sites over-report events may not 
be as high as we found. Additionally, there may be other 
reasons to adjudicate in randomized trials, which can have 
benefits that are more difficult to quantify. Central adjudi-
cation could identify poorly performing sites or even act as 
a policing effect that strengthens local assessment as inves-
tigators assess outcomes that are to be adjudicated more 
thoroughly.
Before the inclusion of central adjudication in a clin-
ical trial, the costs should also be considered. In one car-
diovascular trial,43 the total cost of the adjudication process 
was estimated at $125 000 or $72 per adjudicated case. If 
regulators and academic reviewers continue to advocate ad-
judication for the purpose of ensuring validity of results, 
then trialists will have no choice but to include potentially 
redundant adjudication committees, which in turn will lead 
Figure 4. Meta-analysis of change in number of reported events in included studies, using a random-effects model. RTE indicates ratio of treatment effects.
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to excessive research waste.16,17,44 In this review, we have not 
attempted to estimate the cost of adjudication, but this seems 
to be the next challenge to establish the role of adjudica-
tion in clinical trials. If the cost can be accurately predicted, 
then trialists can decide during the study design stage of a 
trial what they (and the funder and their reviewers) will be 
prepared to fund for adjudication and its potential, unmeas-
urable benefit.
One limitation of our review is that while we identified a 
total of 89 trials that were potentially eligible, we only man-
aged to receive data from 15 of these, even after 3 remind-
ers.24 A large proportion of studies that did not provide data 
mentioned that the unadjudicated data were not available, 
and it is possible that our review may have found different 
results had more trials provided data. However, the charac-
teristics of the excluded studies were similar to those that 
were included, and the individual results from all 15 included 
trials agreed with the overall pooled estimate. Another lim-
itation of our small sample size is that the included studies 
are high-quality trials in respect to the usual components of 
risk of bias, and higher quality studies could have less need 
for adjudication than lower quality trials. Furthermore, our 
review largely included prevention stroke trials and studies 
with binary primary outcomes. A larger sample of trials that 
had greater variation in quality, type, and outcome could po-
tentially have different findings. In our protocol, we stated 
that we would investigate the impact of adjudication on RTE 
by subjectivity of the outcome, but we did not undertake 
this analysis. This was because all the included outcomes 
are common in stroke trials and are sufficiently objective to 
change clinical practice.
Of further interest would be to identify the number of 
events that need to be misclassified before the RTE differs 
from one. This would give an estimate for the magnitude of 
disagreement required between central adjudicators and site 
investigators to alter the estimated treatment effect. In addi-
tion, for borderline cases (where one limit of the CI for the 
estimated treatment effect lies close to the null value) even a 
small amount of misclassification could miss a genuine treat-
ment effect. However, determining at the design stage whether 
a study risks failing to detect a treatment effect because of 
misclassification of outcomes by site investigators is chal-
lenging. We plan to conduct further research using simulation 
studies to investigate these questions.
In summary, this review found no evidence that central 
adjudication of the primary outcome in stroke trials had any 
impact on estimated treatment effect size. However, central 
adjudication did control nondifferential misclassification and 
limit over-reporting of events by site investigators. If the pri-
mary purpose of central adjudication is to ensure the validity 
of trial conclusions, then these results suggest that the poten-
tial advantages of central adjudication may not outweigh cost 
and time disadvantages in stroke studies.
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